Antibody–drug conjugates:
Why the delivery system matters.

Three parts, one medicine.

An antibody–drug conjugate, or ADC, joins a targeting antibody to a small-molecule drug through a chemical linker. The objective is straightforward: concentrate a potent treatment where it can do useful damage while limiting exposure elsewhere. FDA treats the linked medicine and its constituent parts as important to understanding both benefit and harm. [1]

Follow the medicine into the cell.

Padcev, or enfortumab vedotin, provides a concrete example. Its antibody recognizes Nectin-4. It carries MMAE, a drug that disrupts microtubules—the structures cells need to divide—attached through a linker that can be cut by enzymes. [2]

1. Bind: the antibody attaches to its target at the cell surface.
2. Enter: the cell takes in the bound ADC.
3. Release: processing inside the cell liberates the payload.
4. Disrupt: MMAE interferes with the cell’s division machinery, leading to cell death.

This is a useful description of Padcev’s mechanism, not a universal rule for every construct or every route of payload release. An ADC is a designed combination; changing one component can change how the whole medicine behaves. [2]

Cancer is a mixed neighborhood.

Cells within a tumor need not display the same amount of a target. A delivery system that reaches only the most strongly positive cells can leave others behind. Some ADC payloads can cross cell membranes after release and affect nearby cells—the bystander effect.

In experiments with the molecule subsequently known as trastuzumab deruxtecan, researchers demonstrated activity against neighboring HER2-negative cells in mixed cell populations and mouse models. Payload permeability helped explain the effect. That is mechanistic, preclinical evidence: it explains a possible advantage rather than independently proving a survival benefit in patients. [3]

The engineering question becomes more interesting than “Does the antibody bind?” It is also “Where does the released drug go?” Greater reach can be useful in an uneven tumor, but selectivity still has to be assessed for the complete medicine.

The advantage has to appear in patients.

Two randomized studies illustrate what this technology can achieve. They address different diseases and populations and cannot be used to rank the drugs against one another.

These medians describe study populations, not a promised number of months for an individual. Enhertu is a Daiichi Sankyo–AstraZeneca medicine; it is included as evidence about ADC science, not as an asset Pfizer acquired with Seagen. [5]

Why Pfizer bought Seagen.

Pfizer completed its acquisition in December 2023 at an enterprise value of approximately $43 billion. Seagen brought three marketed ADCs—Adcetris, Padcev and Tivdak—along with the targeted medicine Tukysa, development programs and substantial ADC expertise. Tukysa is not an ADC. The transaction was about established medicines and a capability to develop more of them. [6]

Our interpretation: the strategic appeal was the combination of clinical validation and accumulated know-how. Identifying a target is one problem. Repeatedly connecting the right antibody, release chemistry and drug into a usable therapy is another. Acquiring a team and technology with demonstrated results can be more valuable than acquiring an attractive scientific idea.

That explains the scientific rationale. Whether $43 billion was an attractive price requires a separate assessment of retained economics, partnership rights, development spending, competition and the durability of future cash flows. Strong science makes a business possible; it does not settle its valuation.

Targeted does not mean harmless—or inevitable.

Padcev’s clinical experience includes risks such as skin reactions, high blood glucose and peripheral neuropathy, or nerve damage. [4] Enhertu carries a boxed warning for interstitial lung disease and pneumonitis, which can be fatal. Its 2024 tumor-agnostic HER2-positive approval was accelerated and based on response evidence, with continued approval potentially dependent on confirmation of clinical benefit. Mechanistic appeal, tumor shrinkage and proven survival benefit are different levels of evidence. [7]

What the next advances must deliver.

ADCs are not a brand-new invention. FDA described decades of regulatory experience when explaining its 2024 guidance. The opportunity lies in improving the performance of the complete construct, including the relationship between dose, exposure, efficacy and toxicity. [1]

We would judge a proposed advance against four practical questions:

• Reach: does it deliver useful drug activity to the cells that matter, including a tumor’s less uniform regions?
• Control: does release occur where intended, and is unintended exposure tolerable?
• Benefit: does it improve a meaningful outcome against a relevant alternative in the intended patients?
• Repeatability: can the result hold across studies, treatment settings and ordinary clinical use?

A new target or more elaborate chemistry is a reason to investigate. It is not itself the clinical advantage. The important advance is a treatment that does more for patients at an acceptable cost in toxicity.

Terms worth knowing

Antigen

A molecular feature an antibody recognizes; in these examples, a protein associated with the cell surface.

Conjugation

Chemically attaching the drug and linker to the antibody.

Payload

The active small-molecule drug carried by the ADC.

Bystander effect

Activity of released payload against neighboring cells, potentially including cells without the targeted antigen.

Overall survival

Time until death from any cause. A trial’s median is the point at which its estimated survival curve reaches 50%.

Therapeutic window

The range of exposure in which useful treatment activity can be achieved without unacceptable toxicity.

← Return to Therapeutic Perspectives